Identification | Back Directory | [Name]
2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride | [CAS]
97657-92-6 | [Synonyms]
CS-784 Dimebon 2HCl DiMebone HCl Latrepirdine 2HCl DiMebone dihydrochloride DiMeboline dihydrochloride Latrepirdine dihydrochloride Dimebone dihydrochloride hydrate Dimebolin dihydrochloride hydrate Dimeboline dihydrochloride hydrate 2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole hydrochloride 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole,dihydrochloride 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indoledihydrochloride 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride 2,8-Dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride hydrate 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride ISO 9001:2015 REACH | [EINECS(EC#)]
692-160-9 | [Molecular Formula]
C21H25N3.2ClH | [MDL Number]
MFCD17215933 | [MOL File]
97657-92-6.mol | [Molecular Weight]
392.371 |
Chemical Properties | Back Directory | [Melting point ]
220-222 °C | [storage temp. ]
Desiccate at RT | [solubility ]
H2O: ≥10mg/mL | [form ]
powder | [color ]
white to off-white | [Water Solubility ]
H2O: ≥10mg/mL |
Hazard Information | Back Directory | [Uses]
Latrepirdine is an antihistamine drug used initially in Russia. Recently research have explore the potential of Latrepirdine to demonstrate activities against neurodegenerative conditions. | [Biological Activity]
Non-selective antihistamine that displays cognitive enhancing abilities. Also displays high affinity for 5-HT (particularly 5-HT 6 and 5-HT 7 ), α -adrenergic, dopaminergic, AMPA and NMDA receptors, and L-type calcium channels. Exhibits neuroprotective activity in cellular models of Alzheimer's and Huntington's disease and preserves cognitive function following administration to AF64A lesioned rats. Protects neurons against the neurotoxic action of β -amyloid fragment. | [in vivo]
Latrepirdine treatment of TgCRND8 transgenic mice is associated with improved learning behavior and with a reduction in accumulation of Aβ42 and α-synuclein. Male, 90-day-old TgCRND8 mice or their wild-type littermates (nTg) receive 31 consecutive once daily i.p. injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). At the culmination of treatment, mice are tested for cued and contextual fear conditioning using a paradigm that has been widely accepted for evaluating learning and memory deficits in APP transgenic mice. A significant increase in cued memory only among Latrepirdine-versus vehicle-treated TgCRND8 mice (p=0.01) is observed. A weak, non-significant trend toward an improvement in contextual memory among Latrepirdine-versus vehicle-treated mice (p=0.099) is also observed[1]. | [storage]
Store at -20°C |
|
Company Name: |
|
Tel: |
821-50328103-801 18930552037 |
Website: |
http://m.approvedhomemanagement.com/ShowSupplierProductsList13285/0.htm |
|